Shots:

• Jasper Therapeutics has dosed the first patient with briquilimab in the P-Ib/IIa clinical evaluation for treating chronic inducible urticaria (CIndU)
• The P-Ib/IIa (SPOTLIGHT) trial assesses the safety, efficacy, PK characteristics & tolerability of briquilimab (SC) single administration at two different dose levels for the treatment of patients (n=~15) with cold urticaria (ColdU) or symptomatic dermographism (SD) across the EU. The preliminary results are expected in H2’24
• Briquilimab (formerly JSP191) is a targeted aglycosylated mAb that inhibits the binding of stem cell factor with the cell-surface receptor c-Kit (CD117), blocking receptor signaling

Ref: Jasper Therapeutics | Image: Jasper Therapeutics

Related News:- BioLineRx Reports First Patient Dosing with Motixafortide in P-II Study for the Treatment of Pancreatic Cancer (PDAC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com